Adding a short-term regimen of C1-INH concentrate to the preventive treatment of a 63-year-old man with hereditary angioedema (HAE) enabled a successful tooth extraction without a swelling attack in his larynx, a case study reports. The tailored Orladeyo (berotralstat) prophylaxis regimen was designed to prevent an attack…

Prophylactic, or preventive, treatment with deucrictibant significantly reduced the rate of swelling attacks among adults with hereditary angioedema (HAE) in a Phase 2 clinical trial. “These study results, together with the compelling data from our on-demand program, further strengthens our confidence that deucrictibant can become the preferred option…

Argentina’s regulatory body has approved BioCryst Pharmaceuticals’ Orladeyo (berotralstat) to prevent swelling attacks in adults and adolescents, ages 12 and older, who have hereditary angioedema (HAE). The decision by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) comes a few months after the approval of…

The Phase 3 KONFIDENT trial, which is testing oral sebetralstat as an on-demand treatment for hereditary angioedema (HAE), has achieved its targeted number of on-treatment swelling attacks. The trial can wrap up now that three attacks per patient were treated. Topline data is expected in early 2024. If…

A single subcutaneous or under-the-skin injection of STAR-0215 — an experimental treatment that aims to prevent swelling attacks in people with hereditary angioedema (HAE) — led to a sustained decrease in kallikrein protein activity in healthy adults for close to three months, according to new trial data. Early…

In a clinical trial, most people with hereditary angioedema (HAE) given on-demand treatment with PHVS416, an immediate-release capsule formulation of deucrictibant, saw swelling attacks begin to resolve within half an hour of taking the medication. That’s according to new data presented in a poster, titled “…

The European Commission has expanded the approval of Takhzyro (lanadelumab) to include children with hereditary angioedema (HAE) as young as 2 years of age. This makes Takhzyro the first routine preventive, or prophylactic, treatment for HAE attacks to be approved for patients younger than 6 in the European…

Donidalorsen, an experimental treatment in the pipeline of Ionis Pharmaceuticals, continues to prevent swelling attacks when taken for up to two years, allowing a better quality of life for adults with hereditary angioedema (HAE). These results come from an ongoing open-label extension study (NCT04307381) in HAE…

Most older adults with hereditary angioedema (HAE) have more frequent and severe swelling attacks, and more chronic diseases that combine to have a negative impact on their quality of life, results from a focus group study show. Other age-related difficulties included financial barriers to accessing medication. Despite these challenges,…

Pharvaris is now gearing up startup activities with clinical site investigators and staff to launch a Phase 3 trial next year of PHVS416 — an immediate-release capsule formulation of deucrictibant — as an on-demand treatment for hereditary angioedema (HAE). The Switzerland-based clinical-stage company recently met with the U.S. Food…